Inspira Technologies OXY B.H.N. Ltd. has announced a strategic shift to accelerate the global commercial rollout of its FDA-cleared ART100 system. Following successful clinical implementations in the U.S., the company is actively engaged in discussions with governmental health departments and private organizations to expand the system's reach. This expansion aligns with the growing demand for alternatives to mechanical ventilation and positions Inspira as a key player in scalable respiratory solutions. The company is prioritizing near-term revenue activities while continuing to support its innovation pipeline, including the development of the next-generation INSPIRA™ ART500 and the HYLA™ blood sensor. Deliveries of the ART100 system are expected to begin in the second half of 2025, contingent on the finalization of commercial and legal terms.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.